Dernières nouvelles pour Biohaven (NYSE:BHVN) Stock

Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Pharma Hldgs

Biohaven Pharmaceutical

Biohaven Ltd

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and lowers the price target from $20 to $16.

News

Price Target

Analyst Ratings

IART

Citigroup Maintains Sell on Integra Lifesciences, Lowers Price Target to $16

Evercore ISI Group analyst Vijay Kumar maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and raises the price target from $275 to $278.

Evercore ISI Group Maintains Outperform on Danaher, Raises Price Target to $278

Trading Ideas

On CNBC, Stephanie Link Announced Bought More Truist Financial Corp

The Joe Biden-inspired meme coin Boden (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BODEN</a>) on Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) is showing signs of rebounding from recent lows, up over 75% on the day.
What Happened: According to <a href="https://dexscreener.com/solana/6uybx1x8yucfj8ystpyizbyg7uqzaq2s46zwphumkjg5">data </a>from DexScreener, Boden (BODEN) is currently trading at $0.011, with a market cap of $7.8 million.
The token has seen a 24-hour trading volume of $1.7 million, with buyers outpacing sellers in recent transactions.
&#8220;Uptober + October pre-election hype = $BODEN mooning,&#8221; pseudonymous crypto trader ChimpZoo <a href="https://x.com/ThinkingBitmex/status/1840969501686300944">tweeted</a>, referencing the market&#8217;s seasonal bullish trend.
The trader has been vocal in his belief that the current hype cycle, combined with political momentum ahead of the U.S. elections, could catapult BODEN back to significant highs, rhetorically asking &#8220;Are you ready for $1?&#8221; 
ChimpZoo further <a href="https://x.com/ThinkingBitmex/status/1840844699461906646">emphasized</a> his stance, stating, &#8220;$1 TARGETS STILL ALIVE AND WELL.&#8221;
Despite losing over 99% of its value from its all-time high of $1.08 earlier this year, BODEN&#8217;s recent price movement has caught the attention of market participants. 
ChimpZoo had previously acknowledged the coin&#8217;s risky nature but identified a buying opportunity in the steep price drop. 
In an earlier tweet, he noted, &#8220;There's a real risk this coin goes to zero, but I believe there is a significant chance that we see a 5x-40x in price in the near future.&#8221; 
ChimpZoo has openly disclosed that he has &#8220;loaded a huge bag at these levels,&#8221; demonstrating his confidence in the <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40041501/joe-biden-inspired-boden-meme-coin-down-99-from-its-highs-what-is-going-on">coin&#8217;s future performance.</a>
Boden&#8217;s surge also coincides with increased activity and sentiment in the broader crypto market. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41102705/pay-taxes-with-bitcoin-ohio-senator-proposes-bill-for-crypto-tax-payments-but-theres-a-cat">Pay Taxes With Bitcoin? Ohio Senator Proposes Bill For Crypto Tax Payments, But There&#8217;s A Catch</a>
Why It Matters: The history of BODEN has been turbulent, with previous stories highlighting the <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39885547/meet-the-traders-who-lost-2m-and-8m-betting-on-biden-and-the-jeo-boden-meme-coin">massive losses faced by traders</a> due to its volatility.
In one instance, a trader reportedly saw their investment of $8 million in Boden dwindle down to just $85,000, highlighting the risks associated with meme coins tied to specific narratives. 
Despite these cautionary tales, ChimpZoo remains bullish, attributing the latest rally to the upcoming election cycle and what he calls &#8220;BODENOMICS.&#8221;
The ongoing price action of Boden is indicative of the volatile nature of meme coins, particularly those intertwined with political events and figures. 
With the U.S. presidential election looming and October&#8217;s historical market trends often favoring upward movements, traders like ChimpZoo are betting on another explosive rally. 
The future of BODEN, however, remains uncertain, hinging on both market sentiment and the rapidly shifting dynamics in the world of cryptocurrency.
What&#8217;s Next: The current landscape and the implications for meme coins like BODEN will be key topics at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets </a>event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41114110/the-dollar-is-weakening-heres-why-that-could-be-good-for-bitcoin-10x-research">The Dollar Is Weakening—Here&#8217;s Why That Could Be Good For Bitcoin: 10x Research</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BODEN

$SOL

Joe Biden-Inspired Jeo Boden Meme Coin Leaves Rivals Dogecoin, Shiba Inu In The Dust With 75% Gain

Citigroup analyst Joanne Wuensch maintains Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) with a Neutral and raises the price target from $124 to $130.

ITGR

Citigroup Maintains Neutral on Integer Holdings, Raises Price Target to $130

Union Pacific On U.S. Port Strikes Says Seen A Shift In Volume At West Coast Ports, Handling Record Intermodal Volume In August At Ports Of LA, Long Beach

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) will release its financial results on Oct. 10, 2024 before financial markets open and host a live conference call to discuss the results at 8:30 am ET the same day.
In July, Tilray reported fiscal fourth-quarter revenue of $229.882 million, up approximately 25% year-over-year. Cannabis net revenue increased&nbsp;12%&nbsp;to&nbsp;$71.9 million in the quarter, while beverage-alcohol net revenue jumped&nbsp;137%&nbsp;to&nbsp;$76.7 million for the period.
Irwin Simon, chairman and CEO of Tilray Brands <a href="https://www.benzinga.com/markets/cannabis/24/07/40023244/tilray-q4-earnings-revenue-eps-beat-as-cannabis-beverages-wellness-converge-on-a-global-scale-dr">said at the time</a> that the company is "leading the convergence of cannabis, beverages, and wellness on a global scale."
Simon has spoken at previous Benzinga cannabis events sharing valuable tips for businesses within the burgeoning industry. The upcoming two-day event, the 19th Benzinga Cannabis Capital Conference, returns to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/01101339/ccc-oct-24-banner__1_-2.gif" alt="" class="wp-image-574784" /></a></figure>
<a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a>, senior analyst at Zuanic &amp; Associates <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40036301/tilray-should-be-a-long-term-holding-in-any-global-portfolio-of-cannabis-stocks-say">wrote in his post-earnings</a> analyst note that "TLRY should be a long-term holding in any global portfolio of cannabis stocks,&#8221; adding the company&#8217;s liquidity, large market cap and notable cash balance, plus assets, make it a &#8220;more credible&#8221; long-term investment.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/40076821/tilray-ceo-on-future-of-cannabis-and-federal-rescheduling-we-did-not-sit-back-and-wait">Tilray CEO On Future Of Cannabis And Federal Rescheduling: &#8216;We Did Not Sit Back And Wait&#8217;</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Recent Moves</h3>
In early September, Tilray <a href="https://www.benzinga.com/markets/cannabis/24/09/40690381/billion-dollar-cannabis-company-closes-acquisition-of-three-us-breweries-whats-next-for-tilray">closed on acquisitions</a> of four U.S. breweries from from Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>). The acquisitions of Hop Valley Brewing Company,Terrapin Beer Co., Revolver Brewing and <a href="https://www.benzinga.com/markets/cannabis/24/09/40852419/billion-dollar-marijuana-giant-buys-another-brewery-from-molson-coors-expands-great-lakes-footpr">Atwater Brewery</a>, bolstered the company's leadership position in the U.S. craft beer market as the 5th largest craft brewer in the country and top craft brewer in the Pacific Northwest and Georgia.
Meanwhile, Tilray did not neglect the cannabis side of its business.
In August, the company <a href="https://www.benzinga.com/markets/cannabis/24/08/40510926/tilray-is-not-giving-up-on-cannabis-ramps-up-its-canadian-portfolio-on-heels-of-buying-four-us-b">announced the release</a> of its latest small-batch flower strain, Milk &amp; Cookies, under its premium cannabis brand Broken Coast.
In addition to the launch of Redecan EU-GMP-certified medical <a href="https://www.benzinga.com/topic/australia">marijuana products in Australia,</a> Tilray also introduced a new line of hemp-derived Delta-9 THC <a href="https://www.benzinga.com/markets/cannabis/24/09/41009554/tilray-brands-launches-hemp-derived-delta-9-thc-drinks-in-key-u-s-markets">beverages across key U.S. markets in September</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40901036/tilray-acquires-23-8m-promissory-note-in-deal-with-double-diamond-on-heels-of-brewery-acquisitio">&nbsp;Tilray Acquires $23.8M Promissory Note In Deal With Double Diamond On Heels Of Brewery Acquisition</a></li>
</ul>
<h3 class="wp-block-heading">TLRY Price Action</h3>
Tilray's shares traded 0.8523% lower at $1.745 per share at the time of writing on Tuesday morning.

Cannabis

Earnings

TLRY

Billion-Dollar Cannabis Giant Tilray To Report Earnings, Here's What Investors Can Expect

Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $250 to $275.

PODD

Citigroup Maintains Buy on Insulet, Raises Price Target to $275

WIIM

$BTC

$ETC

$ETH

$LTC

Shares of cryptocurrencies are trading lower amid a drop in the price of Bitcoin. Shares of the assets are falling as tensions rise in the Middle East following reports suggesting that Iran could be preparing to attack Israel.

Silexion Therapeutics Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock is trading higher on Tuesday with a strong session volume of 36.4 million versus the average volume of 2.65 as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Silexion released new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41113258/silexion-therapeutics-reports-breakthroughs-from-sil-204-preclinical-studies" rel="noreferrer noopener">extended-release formulation</a>.
<ul>
<li>SIL-204 demonstrated substantial tumor reduction in human pancreatic tumor cell lines with the KRAS G12D (Panc -1) mutations using the oncogene silencing approach with siRNA.</li>
<li>Previous studies showed this effect using unformulated siRNA with daily injections.</li>
<li>The new studies further show this effect with a single administration of SIL-204 encapsulated in an extended-release formulation.</li>
<li>Moreover, histopathological examination of treated tumors showed a very high induction of tumor necrosis.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41004155/silexion-therapeutics-stock-trades-higher-trial-data-for-pancreatic-cancer-patients-shows-promise" rel="noreferrer noopener">Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise</a>.
The transition from PLGA depot rods to PLGA microparticles (MPs) has resulted in a superior extended-release profile, enhancing the therapeutic potential.
We now report in vivo results indicating that our new modified PLGA-microparticle formulation has superior properties over previous extended-release formulations (Loder).
Silexion plans to initiate toxicology studies with SIL-204 within the upcoming months and advance it into Phase 2/3 trials in the first half of 2026, focusing initially on locally advanced pancreatic cancer (LAPC), which has a notoriously high mortality rate.
In parallel, the company plans to initiate preclinical studies for SIL-204 in colorectal cancer models.
Silexion CEO Ilan Hadar said the improvements in cellular uptake and the enhanced extended-release formulation &#8220;further strengthen&#8221; the company&#8217;s confidence in SIL-204&#8217;s potential. 
&#8220;We look forward to commencing our next set of studies in preparation for our Phase 2/3 clinical trial,&#8221; Hadar said. 
Price Action: Silexion stock is up .29% at 53 cents at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41115344/cvs-health-mulls-split-of-retail-and-insurance-divisions-to-address-financial-challenges-report" target="_blank" rel="noreferrer noopener">CVS Health Mulls Split Of Retail And Insurance Divisions To Address Financial Challenges: Report</a>.</li>
</ul>

Biotech

Health Care

Movers

General

SLXN

Silexion Investigational Pancreatic Cancer Treatment Shows Promise In Animal Studies

Citigroup analyst Joanne Wuensch maintains Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) with a Neutral and raises the price target from $45 to $50.

ESTA

Citigroup Maintains Neutral on Establishment Labs Hldgs, Raises Price Target to $50

Biden Says On Negotiations Between USMX And The International Longshoremen's Association: Collective Bargaining Is Best Way For Workers To Get Pay And Benefits They Deserve; It Is Time For USMX To Negotiate A Fair Contract With Longshoremen; My Administration Will Be Monitoring For Any Price Gouging Activity That Benefits Foreign Ocean Carriers, Including Those On USMX Board

Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and lowers the price target from $83 to $77.

Citigroup Maintains Buy on Edwards Lifesciences, Lowers Price Target to $77

Legal

SNAP

Snap Issues Statement On New Mexico Attorney General's Complaint; Says Have Made Deliberate Design Choices To Make It Difficult For Strangers To Discover Minors On Service, Continue To Evolve Safety Mechanisms & Work Alongside Law Enforcement And Government Agencies For Stronger Defenses

Evercore ISI Group analyst Vijay Kumar maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a In-Line and raises the price target from $17 to $19.

BLCO

Evercore ISI Group Maintains In-Line on Bausch & Lomb, Raises Price Target to $19

Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Neutral and raises the price target from $38 to $40.

Citigroup Maintains Neutral on Baxter Intl, Raises Price Target to $40

Evercore ISI Group analyst Vijay Kumar maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Outperform and raises the price target from $286 to $290.

Evercore ISI Group Maintains Outperform on Becton Dickinson, Raises Price Target to $290

HC Wainwright &amp; Co. analyst Joseph Pantginis downgrades Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) from Buy to Neutral.

Downgrades

STTK

HC Wainwright & Co. Downgrades Shattuck Labs to Neutral

Analog Devices's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NYSE">ADI</a>) short percent of float has fallen 4.02% since its last report. The company recently reported that it has 8.28 million shares sold short, which is 1.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Analog Devices Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727799322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Analog Devices has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Analog Devices's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Analog Devices's peer group average for short interest as a percentage of float is 4.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(ADI) - Analyzing Analog Devices's Short Interest

With the recent <a href="https://www.benzinga.com/news/24/09/40970727/federal-reserves-bold-rate-cut-retail-sales-rise-and-more-this-week-in-economics">Federal Reserve rate cuts</a>, many homeowners wonder if now is the time to refinance. After all, this decision has lowered mortgage rates to the lowest in about two years, making it much more tempting if you're locked into a higher rate. But, according to personal finance expert and Ramsey Show co-host <a href="https://www.benzinga.com/personal-finance/24/08/40288004/the-ramsey-show-hosts-tell-65-year-old-retiree-to-start-pulling-social-security-instead-of-livin">Jade Warshaw</a>, waiting might be worth it.&nbsp;
Don't Miss:
<ul>
<li>Beating the market through ethical real estate investing' — t<a href="https://www.benzinga.com/money/invest-with-roots">his platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>
In a recent guest appearance on Fox Business, Warshaw discussed the recent rate cuts and their implications for personal debt from credit cards to mortgages. While the rate cuts might entice some to go further into debt by taking out loans or credit with lower rates, Warshaw said the only consumers who benefit from this right now are those in the market to buy a home.&nbsp;
Along that same line of thinking, Warshaw warned those thinking about refinancing their homes to hold off for a beat. "If you bought at the height of rates, you are itching right now to refinance," she told Fox Business. "But I do think it&#8217;s worth it to wait."
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?
<hr class="wp-block-separator has-alpha-channel-opacity" />
She said those wanting to refinance don't necessarily have to wait a long time, but it would be wise to wait until after the election to see where all the chips fall. She also touched on the fact that <a href="https://www.benzinga.com/markets/24/08/40474135/does-it-pay-to-refinance-yet-heres-how-to-do-the-math">refinancing is expensive</a>.
According to Bankrate, refinancing a mortgage can cost between two and five percent of the new loan. For a $244,498 loan – the average American's mortgage debt – you're looking at anywhere from $4,800 to $12,225. And that's just on the average. Costs could also be associated with the refinancing application, origination and home appraisal fees.&nbsp;
The Fed's recent rate cut was its first since March 2020, and more reductions are expected through 2025. According to Freddie Mac, the average 30-year fixed mortgage rate recently fell to 6.08%, the lowest in two years. However, predictions suggest rates could dip even further, potentially reaching the mid-5% range by the end of the year.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Interest rates could be further impacted by the upcoming election. According to Warshaw, election cycles can influence economic policy and interest rates, so it's smart to make big financial decisions like refinancing after the election.&nbsp;
It's also worth noting that while the Fed's rate cuts have led to slightly lower mortgage rates, other lending products such as credit cards and auto loans have not seen the same level of relief. The reduction in credit card APRs has been minimal, offering only modest consumer savings. So, while <a href="https://www.benzinga.com/news/24/09/40921345/mortgage-rates-drop-to-2-year-low-refinancing-hits-fastest-pace-since-2022-rocket-lendingtree-among">mortgage refinancing</a> may become more favorable in the coming months, it&#8217;s important not to overextend by taking on new debt in other areas.
If you&#8217;re considering refinancing or purchasing a home, keep an eye on the market, especially as more rate cuts are expected. By staying informed and patient, you may secure a better financial future with lower rates and fewer expenses.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
<li>Groundbreaking trading app with a ‘Buy-Now-Pay-Later' feature for stocks tackles the $644 billion margin lending market –<a href="https://www.benzinga.com/money/wolfpack"> here&#8217;s how to get equity in it with just $500</a></li>
</ul>

Real Estate

Ramsey Show Host Jade Warshaw Says 'Wait Until After The Election To Refinance Your Home,' That This Isn't The Last Rate Drop

RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price target of $68.00. T...

RBC Capital Remains a Buy on Biohaven Ltd. (BHVN)

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target at $58.00....

Buy Rating Affirmed for Biohaven Ltd. on Strong Potential of Troriluzole for Spinocerebellar Ataxia

Analyst Thomas Shrader from BTIG maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target at $59.00. Thomas S...

Buy Rating for Biohaven's Troriluzole Backed by Long-Term Efficacy Data and Positive Regulatory Outlook

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price targe...

Buy Rating Affirmed for Biohaven Ltd. on Promising Troriluzole SCA Program Data and Potential Market Dominance

In a report released yesterday, William Pickering from Bernstein maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price ta...

Bernstein Remains a Buy on Biohaven Ltd. (BHVN)

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on BHVN stock, giving a Buy rating today. Tessa Romero has given his Buy ratin...

Buy Rating Affirmed for Biohaven on Promising Troriluzole SCA Study Results and FDA Approval Potential

Biohaven Ltd. (BHVN) has received a new Buy rating, initiated by Jefferies analyst, Amy Li. Amy Li's rating is based on the promising outcomes of B...

Biohaven Ltd.: Strong Buy Rating on Troriluzole's Promising SCA Study and FDA Alignment

Biohaven proposed public offering of common shares

Biohaven prices $250M share offering

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of...

TD Cowen Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)

BHVN

Press Releases

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Management

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Offerings

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

BNTC

REGN

Arcellx

ADMA Biologics

Alkermes

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Denali Therapeutics

Dyne Therapeutics

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Comments

Biohaven

Actualités

Dernières nouvelles pour Biohaven (NYSE:BHVN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL